These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37898477)

  • 1. Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory.
    Zhang L; Ma J; Liu L; Li G; Li H; Hao Y; Zhang X; Ma X; Chen Y; Wu J; Wang X; Yang S; Xu S
    Crit Rev Oncol Hematol; 2023 Dec; 192():104192. PubMed ID: 37898477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational implications of tumor heterogeneity.
    Jamal-Hanjani M; Quezada SA; Larkin J; Swanton C
    Clin Cancer Res; 2015 Mar; 21(6):1258-66. PubMed ID: 25770293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
    Gerlinger M; Swanton C
    Br J Cancer; 2010 Oct; 103(8):1139-43. PubMed ID: 20877357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Cancer Treatment Using Game Theory: A Review.
    Stanková K; Brown JS; Dalton WS; Gatenby RA
    JAMA Oncol; 2019 Jan; 5(1):96-103. PubMed ID: 30098166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darwinian Approaches for Cancer Treatment: Benefits of Mathematical Modeling.
    Belkhir S; Thomas F; Roche B
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapy.
    Orlando PA; Gatenby RA; Brown JS
    Phys Biol; 2012 Dec; 9(6):065007. PubMed ID: 23197192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory.
    Gluzman M; Scott JG; Vladimirsky A
    Proc Biol Sci; 2020 Apr; 287(1925):20192454. PubMed ID: 32315588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosage strategies for delaying resistance emergence in heterogeneous tumors.
    Vakil V; Trappe W
    FEBS Open Bio; 2021 May; 11(5):1322-1331. PubMed ID: 33638275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
    Kim JY; Gatenby RA
    Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer.
    S A; Chakraborty A; Patnaik S
    Mutat Res Rev Mutat Res; 2022; 790():108445. PubMed ID: 36371022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.
    Lim ZF; Ma PC
    J Hematol Oncol; 2019 Dec; 12(1):134. PubMed ID: 31815659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards Multidrug Adaptive Therapy.
    West J; You L; Zhang J; Gatenby RA; Brown JS; Newton PK; Anderson ARA
    Cancer Res; 2020 Apr; 80(7):1578-1589. PubMed ID: 31948939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Evolution and Ecology of Resistance in Cancer Therapy.
    Gatenby RA; Brown JS
    Cold Spring Harb Perspect Med; 2020 Nov; 10(11):. PubMed ID: 33139405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.
    Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA
    Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Evolution and Ecology of Resistance in Cancer Therapy.
    Gatenby R; Brown J
    Cold Spring Harb Perspect Med; 2018 Mar; 8(3):. PubMed ID: 28710258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico implementation of evolutionary paradigm in therapy design: Towards anti-cancer therapy as Darwinian process.
    Brutovsky B; Horvath D
    J Theor Biol; 2020 Jan; 485():110038. PubMed ID: 31580834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
    Chisholm RH; Lorenzi T; Clairambault J
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting evolution to treat drug resistance: combination therapy and the double bind.
    Basanta D; Gatenby RA; Anderson AR
    Mol Pharm; 2012 Apr; 9(4):914-21. PubMed ID: 22369188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the effect of acquired resistance on cancer therapy outcomes.
    Masud MA; Kim JY; Kim E
    Comput Biol Med; 2023 Aug; 162():107035. PubMed ID: 37276754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing Tumor Evolution to Circumvent Resistance.
    Pogrebniak KL; Curtis C
    Trends Genet; 2018 Aug; 34(8):639-651. PubMed ID: 29903534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.